[go: up one dir, main page]

MX2025003876A - Compuestos para el tratamiento de enfermedades mediadas por alfa-1 antitripsina - Google Patents

Compuestos para el tratamiento de enfermedades mediadas por alfa-1 antitripsina

Info

Publication number
MX2025003876A
MX2025003876A MX2025003876A MX2025003876A MX2025003876A MX 2025003876 A MX2025003876 A MX 2025003876A MX 2025003876 A MX2025003876 A MX 2025003876A MX 2025003876 A MX2025003876 A MX 2025003876A MX 2025003876 A MX2025003876 A MX 2025003876A
Authority
MX
Mexico
Prior art keywords
compounds
novel compounds
compositions
combinations
antitrypsin
Prior art date
Application number
MX2025003876A
Other languages
English (en)
Inventor
Kate Smith
Alexis Denis
Nerina Dodic
John Liddle
David Lomas
Original Assignee
Ucl Business Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1810290.5A external-priority patent/GB201810290D0/en
Priority claimed from GBGB1906708.1A external-priority patent/GB201906708D0/en
Application filed by Ucl Business Ltd filed Critical Ucl Business Ltd
Publication of MX2025003876A publication Critical patent/MX2025003876A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a compuestos, composiciones, combinaciones y medicamentos que contienen dichos compuestos y procesos para su preparación. La invención también se refiere al uso de dichos compuestos, combinaciones, composiciones y medicamentos, por ejemplo, como moduladores de alfa 1 antitripsina y para el tratamiento de enfermedades asociadas con alfa antitripsina, particularmente enfermedades del hígado.
MX2025003876A 2018-06-22 2020-12-16 Compuestos para el tratamiento de enfermedades mediadas por alfa-1 antitripsina MX2025003876A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1810290.5A GB201810290D0 (en) 2018-06-22 2018-06-22 Novel Compounds
GBGB1906708.1A GB201906708D0 (en) 2019-05-13 2019-05-13 Novel compounds
PCT/GB2019/051761 WO2019243841A1 (en) 2018-06-22 2019-06-21 Novel compounds

Publications (1)

Publication Number Publication Date
MX2025003876A true MX2025003876A (es) 2025-05-02

Family

ID=67139769

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020013853A MX2020013853A (es) 2018-06-22 2019-06-21 Compuestos innovadores.
MX2025003876A MX2025003876A (es) 2018-06-22 2020-12-16 Compuestos para el tratamiento de enfermedades mediadas por alfa-1 antitripsina

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2020013853A MX2020013853A (es) 2018-06-22 2019-06-21 Compuestos innovadores.

Country Status (10)

Country Link
US (3) US20210276952A1 (es)
EP (1) EP3810131A1 (es)
CN (1) CN113286586A (es)
AU (2) AU2019289228B2 (es)
BR (1) BR112020026314A2 (es)
CA (1) CA3103920C (es)
IL (2) IL279526B1 (es)
MX (2) MX2020013853A (es)
SG (1) SG11202012765PA (es)
WO (1) WO2019243841A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210089656A (ko) 2018-10-05 2021-07-16 버텍스 파마슈티칼스 인코포레이티드 알파-1 항트립신 조절제
GB201820450D0 (en) 2018-12-14 2019-01-30 Z Factor Ltd Compound and its use for the treatment of alpha1-antitryspin deficiency
UY38696A (es) 2019-05-14 2020-11-30 Vertex Pharma Moduladores de alfa-1 antitripsina
GB201918414D0 (en) 2019-12-13 2020-01-29 Z Factor Ltd Compounds and their use for the treatment of Alpha1-Antitrypsin deficiency
GB201918416D0 (en) 2019-12-13 2020-01-29 Z Factor Ltd Compounds and their use for the treatment of Alpha1-Antitrypsin deficiency
GB201918410D0 (en) 2019-12-13 2020-01-29 Z Factor Ltd Compounds and their use for the treatment of alpha1-antitrypsin deficiency
GB201918404D0 (en) 2019-12-13 2020-01-29 Z Factor Ltd Compounds and their use for the treatment of aplha1-antitrypsin deficiency
GB201918413D0 (en) 2019-12-13 2020-01-29 Z Factor Ltd Compounds and their use for the treatment of alpha1-antitrypsin deficiency
IL296750A (en) * 2020-04-03 2022-11-01 Vertex Pharma Pyrrolo[2,3-f]indazole and 2,4,5,10-tetrazatricyclo[7.3.0.03,7]dodeca-1,3(7),5,8,11-pentaene derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (aatd)
US12502376B2 (en) 2020-04-03 2025-12-23 Vertex Pharmaceuticals Incorporated Pyrano[4,3-b]indole derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (AATD)
CA3179333A1 (en) * 2020-04-03 2021-10-07 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
WO2021203028A1 (en) * 2020-04-03 2021-10-07 Vertex Pharmaceuticals Incorporated 7- or 8-hydroxy-isoquinoline and 7- or 8-hydroxy-quinoline derivatives as alpha-1 -antitrypsin modulators for treating alpha-1 -antitrypsin deficiency (aatd)
EP4132908A1 (en) * 2020-04-03 2023-02-15 Vertex Pharmaceuticals Incorporated Indole derivatives as alpha-1 -antitrypsin modulators for treating alpha-1 -antitrypsin deficiency (aatd)
GB202009074D0 (en) 2020-06-15 2020-07-29 Z Factor Ltd Compound
GB202108523D0 (en) 2021-06-15 2021-07-28 Z Factor Ltd Compositions and their use for the treatment of alpha1-antitrypsin deficiency
CN113801053B (zh) * 2021-11-01 2023-09-08 上海皓鸿生物医药科技有限公司 一种制备7-氟-2-氧代吲哚啉-4-羧酸的方法
WO2025049912A1 (en) 2023-08-31 2025-03-06 Biomarin Pharmaceutical Inc. Methods of manufacturing highly stereochemically pure inhibitors of z-at polymerization
WO2025049936A1 (en) 2023-08-31 2025-03-06 Biomarin Pharmaceutical Inc. Solid forms of n-1-(2-chloro-3-fluorophenyl)-1-hydroxypentan-2-yl)-7-fluoro-2-oxoindoline-4-carboxamide and methods of their preparation
WO2025049929A1 (en) * 2023-08-31 2025-03-06 Biomarin Pharmaceutical Inc. Dosage forms of n-(1-(2-chloro-3-fluorophenyl)-1-hydroxypentan-2-yl)-7-fluoro-2-oxoindoline-4-carboxamide and methods of their preparation and use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3818830A1 (de) * 1988-06-03 1989-12-14 Boehringer Mannheim Gmbh Bicyclische carboxamide, verfahren zu ihrer herstellung, deren vorstufen, und diese verbindungen enthaltende arzneimittel
AU679511B2 (en) 1993-03-17 1997-07-03 Minnesota Mining And Manufacturing Company Aerosol formulation containing an ester-, amide-, or mercaptoester-derived dispersing aid
US6126919A (en) 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
US7232818B2 (en) * 2004-04-15 2007-06-19 Proteolix, Inc. Compounds for enzyme inhibition
US9801637B2 (en) 2006-03-13 2017-10-31 Pneumrx, Inc. Genetically-associated chronic obstructive pulmonary disease treatment
EP2114141A2 (en) 2007-01-10 2009-11-11 University of Florida Compounds and methods for treatment of alpha-1 antitrypsin deficiency
KR101402702B1 (ko) 2011-09-15 2014-06-05 (주)알테오젠 신규한 알파-1 안티트립신 변이체, 이의 제조방법 및 용도
ES2863225T3 (es) * 2015-12-03 2021-10-11 Glaxosmithkline Ip Dev Ltd Dinucleótidos cíclicos purinos como moduladores del sting
CN113801053B (zh) 2021-11-01 2023-09-08 上海皓鸿生物医药科技有限公司 一种制备7-氟-2-氧代吲哚啉-4-羧酸的方法

Also Published As

Publication number Publication date
US20220340525A1 (en) 2022-10-27
EP3810131A1 (en) 2021-04-28
CA3103920A1 (en) 2019-12-26
WO2019243841A1 (en) 2019-12-26
US20210276952A1 (en) 2021-09-09
IL279526B1 (en) 2026-01-01
IL279526A (en) 2021-01-31
IL325356A (en) 2026-02-01
CA3103920C (en) 2025-09-16
SG11202012765PA (en) 2021-01-28
BR112020026314A2 (pt) 2021-03-30
AU2019289228B2 (en) 2024-11-14
MX2020013853A (es) 2021-05-27
AU2025200968A1 (en) 2025-03-06
US11919856B2 (en) 2024-03-05
US20240400513A1 (en) 2024-12-05
AU2019289228A1 (en) 2021-01-21
CN113286586A (zh) 2021-08-20
NZ771565A (en) 2025-08-29

Similar Documents

Publication Publication Date Title
MX2025003876A (es) Compuestos para el tratamiento de enfermedades mediadas por alfa-1 antitripsina
MY209609A (en) Immunomodulators, compositions and methods thereof
DOP2018000240A (es) Derivados de piridiniltriazol sustituidos con amida y usos de estos
EA201990495A1 (ru) Биарильные соединения, применимые в качестве иммуномодуляторов
PH12020550051B1 (en) Glp-1 compositions and uses thereof
PH12017501921A1 (en) Novel compounds
CL2019002255A1 (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas.
WO2018226622A8 (en) Compounds for treating huntington's disease
SG10201907164SA (en) Rna containing composition for treatment of tumor diseases
GEAP202014820A (en) Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors
BR112016028255A2 (pt) agentes imunorreguladores
SG10201908839QA (en) 2,4-dihydroxy-nicotinamides as apj agonists
CL2022001178A1 (es) Ligandos de la pseudoquinasa tyk2
MX2022005775A (es) Compuestos terapeuticos y metodos de uso.
EA202090448A1 (ru) Дигидрооксадиазиноны
UY37221A (es) Derivados de feniltriazol sustituidos con amida y usos de estos
MX2019008256A (es) Derivados de bis-heteroarilo biciclicos como moduladores de agregacion de proteinas.
MY207469A (en) Therapeutic compounds
WO2019224790A3 (en) Prodrugs of fulvestrant
TR201900148T4 (tr) Kansere karşı yeni maddeler olarak sübstitüe edilmiş 2,4 diamino-kinolin.
MX2019013419A (es) Compuestos plaguicidas biciclicos.
MY196791A (en) New tetrahydropyrimidodiazepin and dihydropyridodiazepin compounds for treating pain and pain related conditions
HK1257296A1 (zh) 新的化合物及其用途
MX2023001296A (es) Composiciones y metodos para tratar enfermedades y trastornos.
MX2020012281A (es) Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas.